Asthma and chronic obstructive pulmonary disease (Asthma/COPD) are a common type of chronic disease. Once they are sick, they usually need long-term medication, which seriously affects people's quality of life.
Scope of the Report:
This report focuses on the Asthma and COPD Drug in global market, especially in North America, Europe and Asia-Pacific, South America, Middle East and Africa. This report categorizes the market based on manufacturers, regions, type and application.
The 2016 Global Asthma Prevention Initiative (GINA) organization has re-released its Consensus on Asthma, COPD and Asthma-COPD Overlap Syndrome, developed in collaboration with the Global Scientific Committee on Chronic Obstructive Pulmonary Disease Prevention (GOLD). A method of identifying such patients is provided.
The worldwide market for Asthma and COPD Drug is expected to grow at a CAGR of roughly 6.2% over the next five years, will reach 7460 million US$ in 2023, from 5200 million US$ in 2017, according to ...
Table of Contents
1 Market Overview
1.1 Asthma and COPD Drug Introduction
1.2 Market Analysis by Type
1.2.2 Anti-inflammatory Drugs
1.2.3 Monoclonal Antibodies
1.2.4 Combination Drugs
1.3 Market Analysis by Applications
1.4 Market Analysis by Regions
1.4.1 North America (United States, Canada and Mexico)
188.8.131.52 United States Market States and Outlook (2013-2023)
184.108.40.206 Canada Market States and Outlook (2013-2023)
220.127.116.11 Mexico Market States and Outlook (2013-2023)
1.4.2 Europe (Germany, France, UK, Russia and Italy)
18.104.22.168 Germany Market States and Outlook (2013-2023)
22.214.171.124 France Market States and Outlook (2013-2023)
126.96.36.199 UK Market States and Outlook (2013-2023)
188.8.131.52 Russia Market States and Outlook (2013-2023)
184.108.40.206 Italy Market States and Outlook (20 ...